Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Amazon Explores AI Content Marketplace With Media Publishers 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
MELBOURNE, Australia, Nov. 15, 2017 -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), an Australian biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or “molecularly-targeted radiation” (MTR), has today listed on the Australian Securities Exchange (ASX) after raising $50 million in a fully underwritten Initial Public Offering (IPO).
Telix’s issue price is $65c per share, with a market capitalization of $128 million, placing the IPO as the largest for the Australian ASX biotechnology sector, by capital raised, since 1994. The IPO was fully underwritten by the Lead Managers, Taylor Collison Limited and Wilsons Corporate Finance Limited.
The IPO has been strongly supported by existing shareholders, which includes both industry partners and domestic institutional investors such as Acorn Capital, CVC, Monash Investors, Viburnum Funds, Alium Capital Management and Allan Moss. Fidelity International is a cornerstone investor in the IPO at approximately 10% of the issued capital of the Company.
Telix Co-Founder and CEO Dr. Christian Behrenbruch, “We are delighted with the strong support from our partners, institutional and retail investors to make the IPO success We believe this is a very exciting opportunity for investors and we look forward to keeping shareholders closely informed of our progress as we develop our oncology product pipeline and engage with commercial partners.”
Proceeds from the IPO will fund the development and completion of clinical trials for Telix’s pipeline in renal (kidney), prostate and brain cancer (glioblastoma), and enable the Company to complete multiple clinical and product development milestones over the next 24 months.
Corporate Contact Dr Christian Behrenbruch CEO Telix Pharmaceuticals Limited Email: [email protected] Investor and Media Relations Kyahn Williamson WE Buchan Tel: +61 (3) 9866 4722 Email: [email protected]
